Drug intelligence / Profile preview

[68Ga]Ga-NOTA-RCCB3

Development stage: Unknown
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[68Ga]Ga-NOTA-RCCB3 is a **gallium-68 labeled single-domain antibody radiopharmaceutical** designed for immuno-PET/CT imaging of clear cell renal cell carcinoma (ccRCC). It targets CD70, a cell surface protein highly expressed in ccRCC, allowing for specific, noninvasive detection and tumor burden evaluation. The radiotracer consists of the RCCB3 single-domain antibody conjugated with the NOTA chelator for stable gallium-68 radiolabeling. This enables precise PET imaging of CD70-positive lesions in renal cell carcinoma and potentially other malignancies expressing CD70. The agent is administered by intravenous injection and imaged within a short timeframe matching the half-life of gallium-68. In preclinical and early clinical studies, [68Ga]Ga-NOTA-RCCB3 has shown superior specificity and utility compared to non-targeted approaches. Development is ongoing for diagnostic imaging in ccRCC and other CD70-expressing tumors[9].

Other names: [68Ga]Ga-NOTA-RCCB3

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on [68Ga]Ga-NOTA-RCCB3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-NOTA-RCCB3.

Explore the full profile